Advertisement

The effect of G-CSF used after allogeneic hematopoietic stem cell transplantation on engraftment times and platelet suspension replacement numbers

      Abstract

      Background

      With the use of granulocyte colony stimulating factor (G-CSF) after allogeneic hematopoietic stem cell transplantation (HSCT), the duration of neutrophil engraftment and hospitalization were shortened. However, there is no consensus on the effect of G-CSF on platelet engraftment time. The primary aim of our study is to determine the effect of G-CSF use on platelet engraftment time after HSCT. Secondary purposes are to determine the number of platelet suspension, number of erythrocyte suspension and incidence of acute graft versus disease after HSCT.

      Material and methods

      Patients who had allogeneic stem cell transplantation at our center between 01.01.2011 and 01.01.2022 were retrospectively analyzed. Patients were divided into 2 groups as those who received and did not receive G-CSF after transplantation.

      Results

      A total of 64 patients were included. While 32 patients were given post-HSCT G-CSF support, the other 32 patients were not given. Neutrophil engraftment time and length of hospital stay were shorter in the group receiving G-CSF (p < 0.05). Platelet engraftment time was shorter in the group that did not receive G-CSF (p < 0.05). The incidence of acute GVHD of the patients in group 1 tended to be higher than the patients in group 2 (40.6 % vs 15.6 %, p = 0.052). Post-HSCT platelet suspension was less in the group that did not receive G-CSF, but this difference was not statistically significant (p = 0.173).

      Conclusion

      While the positive effect of post HSCT G-CSF use on duration of neutrophil engraftment and hospitalization is evident, its effects on platelet engraftment need to be investigated.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Trivedi M.
        • et al.
        Optimal use of G-CSF administration after hematopoietic SCT.
        Bone Marrow Transplant. 2009; 43: 895-908
        • George G.
        • et al.
        The effect of granulocyte colony-stimulating factor use on hospital length of stay after allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study.
        Biol Blood Marrow Transplant. 2020; 26: 2359-2364
        • Li Y.
        • et al.
        G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes.
        Biochem Pharmacol. 2019; 169113624
        • Chang Y.J.
        • Huang X.J.
        Use of G‐CSF‐stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review.
        Clin Transplant. 2011; 25: 13-23
        • Khoury H.J.
        • et al.
        Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.
        Blood. 2006; 107: 1712-1716
        • Ringden O.
        • et al.
        Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.
        Transplantation. 2010; 90: 1022-1029
        • Singh V.
        • et al.
        G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
        Leuk Lymphoma. 2021; 62: 446-453
        • Battiwalla M.
        • McCarthy P.
        Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice.
        Bone Marrow Transplant. 2009; 43: 351-356
        • Remberger M.
        • et al.
        Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.
        Biol Blood Marrow Transplant. 2011; 17: 1688-1697
        • Remberger M.
        • et al.
        G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV.
        Bone Marrow Transplant. 2003; 32: 217-223
        • Ringdén O.
        • et al.
        Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death.
        Biol Blood Marrow Transplant. 2004; 10: 17
        • Fan Q.
        • et al.
        Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
        J Hematol Oncol. 2017; 10: 1-11
        • Yang J.-Z.
        • Zhang J.-Q.
        • Sun L.-X.
        Mechanisms for T cell tolerance induced with granulocyte colony-stimulating factor.
        Mol Immunol. 2016; 70: 56-62
        • Gupta A.K.
        • et al.
        Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis.
        Am J Blood Res. 2021; 11: 544
        • Sheridan W.P.
        • et al.
        Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
        Lancet. 1992; 339: 640-644